# Edgar Filing: PERRIGO CO - Form 10-Q 

## PERRIGO CO

Form 10-Q
February 01, 2007

```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: DECEMBER 30, 2006
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR \(15(\mathrm{~d})\) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 0-19725
PERRIGO COMPANY
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
```

| MICHIGAN | $38-2799573$ |
| :---: | :---: |
| ------- | -------- |
| (STATE OR OTHER JURISDICTION OF | (I.R.S. EMPLOYER |
| INCORPORATION OR ORGANIZATION) | IDENTIFICATION NO.) |

515 EASTERN AVENUE

ALLEGAN, MICHIGAN 49010
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)
(269) 673-8451
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
NOT APPLICABLE
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or $15(d)$ of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. YES /X/ NO / /

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

LARGE ACCELERATED FILER /X/ ACCELERATED FILER / / NON-ACCELERATED FILER / /

## Edgar Filing: PERRIGO CO - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). / / YES /X/ NO

As of January 29, 2007 the registrant had $92,589,609$ outstanding shares of common stock.

## PERRIGO COMPANY

FORM 10-Q

INDEX


## Edgar Filing: PERRIGO CO - Form 10-Q

future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the company or its industry to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the Company's expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. Please see Item 1A of the Company's Form 10-K for the year ended July 1, 2006 and Item 1A of this Form 10-Q for a discussion of certain important risk factors that relate to forward-looking statements contained in this report. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

$$
-1-
$$

PERRIGO COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share amounts)
(unaudited)

Net sales
Cost of sales

Gross profit

Operating expenses
Distribution
Research and development
Selling and administration
Restructuring

Total

Operating income
Interest, net
Other income, net

| Second Quarter |  |
| :---: | :---: |
| 2007 | 2006 |



| 7,155 | 6,953 |
| ---: | ---: |
| 14,902 | 12,226 |
| 49,239 | 47,082 |
| 642 | -- |
| --------- |  |
| 71,938 | 66,261 |
| 26,387 | 39,309 |
| 3,300 | 5,116 |
| $(2,258)$ | $(5,791)$ |


| Year-to-Date |  |
| :---: | ---: |
| 2007 | 2006 |
| --------- | --------- |
| $\$ 710,844$ | $\$ 679,431$ |
| 517,902 | 486,945 |
| --------- | -------- |
| 192,942 | 192,486 |
| --------- | --------- |


| 14,539 | 14,103 |
| ---: | ---: |
| 27,949 | 24,875 |
| 97,713 | 93,470 |
| 642 | -- |
| --------- |  |
| 140,843 | 132,448 |
| 52,099 | 60,038 |
| 7,886 | 9,142 |
| $(2,319)$ | $(7,037)$ |

## Edgar Filing: PERRIGO CO - Form 10-Q

| Income before income taxes |  | 25,345 |  | 39,984 |  | 46,532 |  | 57,933 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Income tax expense |  | 4,257 |  | 14,618 |  | 8,562 |  | 19,656 |
| Net income | \$ | 21,088 | \$ | 25,366 | \$ | 37,970 | \$ | 38,277 |
| Earnings per share |  |  |  |  |  |  |  |  |
| Basic | \$ | 0.23 | \$ | 0.27 | \$ | 0.41 | \$ | 0.41 |
| Diluted | \$ | 0.23 | \$ | 0.27 | \$ | 0.41 | \$ | 0.41 |
| Weighted average shares outstanding |  |  |  |  |  |  |  |  |
| Basic |  | 91,836 |  | 92,833 |  | 92,104 |  | 93,063 |
| Diluted |  | 93,506 |  | 93,963 |  | 93,595 |  | 94,167 |
| Dividends declared per share | \$ | 0.0450 | \$ | 0.0425 | \$ | 0.0875 | \$ | 0.0825 |

See accompanying notes to condensed consolidated financial statements.

-2-<br>PERRIGO COMPANY<br>CONDENSED CONSOLIDATED BALANCE SHEETS<br>(in thousands)

```
Assets
Current assets
    Cash and cash equivalents
    Investment securities
    Accounts receivable
    Inventories
    Current deferred income taxes
    Prepaid expenses and other current assets
        Total current assets
Property and equipment
    Less accumulated depreciation
Restricted cash
Goodwill
Other intangible assets
Non-current deferred income taxes
Other non-current assets
```

| December 30, | July 1, |
| :---: | :---: |
| 2006 | 2006 |
| ----------- | -------------- |
| (unaudited) |  |


| \$ | 39,635 | \$ | 19,018 |
| :---: | :---: | :---: | :---: |
|  | 34,030 |  | 26,733 |
|  | 246,603 |  | 240,130 |
|  | 322,624 |  | 302,941 |
|  | 50,358 |  | 52,058 |
|  | 24,515 |  | 16,298 |
|  | 717,765 |  | 657,178 |
|  | 629,325 |  | 606,907 |
|  | 308,999 |  | 287,549 |
|  | 320,326 |  | 319,358 |
|  | 400,000 |  | 400,000 |
|  | 188,272 |  | 152,183 |
|  | 134,187 |  | 132,426 |
|  | 46,039 |  | 43,143 |
|  | 47,474 |  | 46,336 |
| \$ | 854,063 | \$ | 750,624 |

            16,298
            657,178
            606,907
            287,549
            319, 358
            400,000
            152,183
            132,426
            43,143
            46,336
    Liabilities and Shareholders' Equity
Current liabilities
Accounts payable
$\$ \quad 173,008$
18,333 20,081

41,049 54,153

## Edgar Filing: PERRIGO CO - Form 10-Q



See accompanying notes to condensed consolidated financial statements.

-3-<br>PERRIGO COMPANY<br>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br>(in thousands)<br>(unaudited)

| Year-To-Date |  |  |  |
| :---: | :---: | :---: | :---: |
| 2007 |  | 2006 |  |
| \$ | 37,970 | \$ | 38,277 |
|  | 27,681 |  | 26,753 |
|  | 5,718 |  | 4,741 |
|  | $(4,248)$ |  | $(7,506)$ |
|  | 67,121 |  | 62,265 |

Changes in operating assets and liabilities Accounts receivable
$(9,295)$
$(23,845)$

| Inventories |  | $(22,919)$ |  | 11,956 |
| :---: | :---: | :---: | :---: | :---: |
| Accounts payable |  | $(4,034)$ |  | 5,480 |
| Payroll and related taxes |  | $(12,658)$ |  | (580) |
| Accrued customer programs |  | $(4,098)$ |  | 9,109 |
| Accrued liabilities |  | (937) |  | $(3,133)$ |
| Accrued income taxes |  | 9,480 |  | $(12,811)$ |
| Other |  | (5,025) |  | 6,797 |
| Sub-total |  | $(49,486)$ |  | $(7,027)$ |
| Net cash from operating activities |  | 17,635 |  | 55,238 |
| Cash Flows (For) From Investing Activities |  |  |  |  |
| Purchase of securities |  | $(117,746)$ |  | $(27,887)$ |
| Proceeds from sales of securities |  | 111,665 |  | 34,586 |
| Additions to property and equipment |  | $(19,784)$ |  | $(12,112)$ |
| Proceeds from sales of property and equipment |  | 2,613 |  | -- |
| Net cash for investing activities |  | $(23,252)$ |  | $(5,413)$ |
| Cash (For) From Financing Activities |  |  |  |  |
| Repayments of short-term debt, net |  | $(1,699)$ |  | $(4,471)$ |
| Borrowings of long-term debt |  | 60,000 |  | 15,000 |
| Repayments of long-term debt |  | $(15,000)$ |  | $(35,000)$ |
| Tax effect of stock transactions |  | (59) |  | (635) |
| Issuance of common stock |  | 3,700 |  | 3,006 |
| Repurchase of common stock |  | $(15,547)$ |  | $(16,401)$ |
| Cash dividends |  | $(8,116)$ |  | $(7,702)$ |
| Net cash (for) from financing activities |  | 23,279 |  | $(46,203)$ |
| Net increase in cash and cash equivalents |  | 17,662 |  | 3,622 |
| Cash and cash equivalents, at beginning of period |  | 19,018 |  | 16,707 |
| Effect of exchange rate changes on cash |  | 2,955 |  | $(4,489)$ |
| Cash and cash equivalents, at end of period | \$ | 39,635 | \$ | 15,840 |
| Supplemental Disclosures of Cash Flow Information Cash paid/received during the period for: |  |  |  |  |
|  |  |  |  |  |
| Interest paid | \$ | 17,062 | \$ | 17,680 |
| Interest received | \$ | 9,831 | \$ | 10,614 |
| Income taxes paid | \$ | 6,727 | \$ | 32,361 |
| Income taxes refunded | \$ | 1,369 | \$ | 5,164 |

See accompanying notes to condensed consolidated financial statements.

$$
\begin{gathered}
\text { PERRIGO COMPANY } \\
\text { NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS } \\
\text { DECEMBER } 30,2006 \\
\text { (in thousands, except per share amounts) }
\end{gathered}
$$

Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products

## Edgar Filing: PERRIGO CO - Form 10-Q

for the store brand market. The Company also develops and manufactures generic prescription (Rx) drugs, active pharmaceutical ingredients (API) and consumer products.

NOTE A -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Article 10 of Regulation $S-X$. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation have been included. The Company has reclassified certain amounts in prior years to conform to the current year presentation.

Operating results for the six months ended December 30, 2006 are not necessarily indicative of the results that may be expected for the full year. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes included in the Company's annual report on Form 10-K for the year ended July 1, 2006.

## New Accounting Pronouncements

In June 2006, the Financial Accounting Standards Board (FASB) issued Interpretation 48, "Accounting for Uncertainty in Income Taxes--an interpretation of FASB Statement 109, Accounting for Income Taxes" (FIN 48), which clarifies the accounting for uncertainty in income taxes. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Interpretation requires that the Company recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The provisions of $\operatorname{FIN} 48$ are effective for fiscal years beginning after December 15, 2006 with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. The adoption of the Interpretation is not expected to have a material impact on the Company's consolidated financial position or results of operations.

In September 2006, the FASB issued Statement of Financial Accounting Standards (SFAS) 157, "Fair Value Measurements". This statement clarifies the definition of fair value, establishes a framework for measuring fair value and expands the disclosures on fair value measurements. SFAS 157 is effective for the Company's fiscal year ending June 27, 2009. The Company has not yet determined if the adoption of this statement will have a material impact on its results of operations or financial position.

$$
-5-
$$

In September 2006, the FASB issued SFAS 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements 87, 88, 106 and $132(R) "$. SFAS 158 requires companies to recognize a net liability or asset and an offsetting net of tax adjustment to accumulated other comprehensive income to report the funded status of defined benefit pension and other postretirement benefit plans. SFAS 158 requires prospective application,

## Edgar Filing: PERRIGO CO - Form 10-Q

and the recognition and disclosure requirements are effective for the Company's fiscal year ending June 30, 2007. Based on preliminary evaluations of SFAS 158, the Company does not expect the adoption of this requirement of the statement to have a material impact on its results of operations or financial position. Additionally, SFAS 158 requires companies to measure plan assets and obligations at their year-end balance sheet date. This requirement is effective for the Company's fiscal year ending June 27, 2009. Since the Company's measurement date currently aligns with its year-end balance sheet date, this requirement will have no impact on the Company's results of operations or financial position.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements" (SAB 108). SAB 108 provides guidance on how prior year misstatements should be taken into consideration when quantifying misstatements in current year financial statements for purposes of determining whether the current year's financial statements are materially misstated. SAB 108 becomes effective during the Company's 2007 fiscal year. The Company does not expect that the adoption of SAB 108 will have a material impact on its results of operations or financial position.

NOTE B -- EARNINGS PER SHARE
A reconciliation of the numerators and denominators used in the basic and diluted earnings per share (EPS) calculation follows:

|  | Second Quarter |  |
| :---: | :---: | :---: |
|  | 2007 | 2006 |
| Numerator: |  |  |
| Net income used for both basic and diluted EPS | \$21,088 | \$25,366 |
| Denominator: |  |  |
| Weighted average shares outstanding for basic EPS | 91,836 | 92,833 |
| Dilutive effect of share-based awards | 1,670 | 1,130 |
| Weighted average shares outstanding for diluted EPS | 93,506 | 93,963 |

Share-based awards outstanding that are anti-dilutive were 2,787 and 4,877 for the second quarters of fiscal 2007 and 2006 , respectively, and 2,702 and 4,374 for year-to-date fiscal 2007 and 2006, respectively. These share-based awards were excluded from the diluted EPS calculation.

$$
-6-
$$

NOTE C -- INVENTORIES

Inventories are summarized as follows:

## Edgar Filing: PERRIGO CO - Form 10-Q

|  | 2006 | 2006 | 2005 |
| :---: | :---: | :---: | :---: |
| Finished goods | \$157,036 | \$148,603 | \$132,841 |
| Work in process | 81,293 | 70,974 | 56,988 |
| Raw materials | 84,295 | 83,364 | 73,026 |
|  | \$322,624 | \$302,941 | \$262,855 |

The Company maintains an allowance for estimated obsolete or unmarketable inventory based on the difference between the cost of inventory and its estimated market value. The inventory balances stated above are net of an inventory allowance of $\$ 39,098$ at December 30, 2006, $\$ 42,509$ at July 1, 2006 and $\$ 44,201$ at December 24, 2005.

NOTE D -- GOODWILL

Goodwill allocated to the Consumer Healthcare segment is tested annually for impairment in the second quarter of the fiscal year. The current year testing resulted in no impairment charge related to the Consumer Healthcare segment. The goodwill allocated to the API and Rx Pharmaceuticals segments is tested for impairment annually in the third quarter of the fiscal year.

There were no acquisitions, dispositions or impairments of goodwill during fiscal 2007. Changes in the carrying amount of goodwill, by reportable segment, are as follows:

|  | Consumer Healthcare | $\frac{\mathrm{Rx}}{\text { Pharmaceuticals }}$ | AP I |
| :---: | :---: | :---: | :---: |
| Balance as of July 1, 2006 | \$44,452 | \$61,406 | \$ 46,325 |
| Goodwill adjustment | -- | 14,877 | 11,223 |
| Currency translation adjustment | 2,363 | 4,366 | 3,260 |
| Balance as of December 30, 2006 | \$46,815 | \$80,649 | \$60,808 |
|  | ===== | $=====$ | $=====$ |

During the first quarter of fiscal 2007 , the Company recorded an adjustment to goodwill for the Rx Pharmaceuticals and API segments. This adjustment was to record a deferred tax liability for income and withholding taxes related to pre-acquisition earnings in an approved enterprise zone in Israel. In accordance with Emerging Issues Task Force 93-7, "Uncertainties Related to Income Taxes in a Purchase Business Combination" (EITF 93-7), the Company treated this item as an uncertain tax position at the time of the acquisition. Until the first quarter of fiscal 2007, the Company was unable to reasonably estimate the liability that was required. Certain factors still remain that could change the ultimate liability and result in subsequent changes in goodwill. Provision has not been made for U.S. or additional foreign taxes on undistributed post-acquisition earnings of foreign subsidiaries because those earnings are considered permanently reinvested in the operations of those subsidiaries.

## Edgar Filing: PERRIGO CO - Form 10-Q

```
NOTE E -- INTANGIBLE ASSETS
Intangible assets and related accumulated amortization consist of the following:
```

|  | December 30, 2006 |  | July 1, 2006 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Gross | Accumulated Amortization | Gross | Accumu Amorti |
| Developed product technology / formulation | \$124,896 | \$15,230 | \$117,615 | \$10 |
| Distribution and license agreements | 19,696 | 4,870 | 18,755 |  |
| Customer relationships | 4,900 | 3,358 | 4,900 |  |
| Trademarks | 9,649 | 1,496 | 9,503 |  |
| Total | \$159,141 | \$24,954 | \$150,773 | \$18 |
|  | ======= | = = = = = = | ======== | = $=$ |

The Company recorded a charge for amortization expense of $\$ 6,424$ and $\$ 6,845$ for the first half of fiscal 2007 and 2006 , respectively, for intangible assets subject to amortization.

The estimated amortization expense for each of the following five years is as follows:

| Fiscal Year | Amount |
| :---: | ---: |
| 2007 (1) |  |
| 2008 | $\$ 5,650$ |
| 2009 | 10,700 |
| 2010 | 11,200 |
| 2011 | 9,300 |
|  | 9,300 |

(1) Reflects remaining six months of fiscal 2007.
-8-

NOTE F -- OUTSTANDING DEBT

Total borrowings outstanding are summarized as follows:

Bank loan -- Germany subsidiary
Bank loans -- Mexico subsidiary

Total

Long-term debt:
Revolving line of credit 125,000
Term loan
100,000
Letter of undertaking -- Israel subsidiary 400,000
Debenture -- Israel subsidiary
43, 784

Total
668,784

Total debt
\$687,117

The terms of the loan related to the letter of undertaking indicated above require that the Company maintain a deposit of $\$ 400,000$ in an uninsured account with the lender as security for the loan. The deposit is classified as restricted cash in the balance sheet as a non-current asset.

NOTE G -- SHAREHOLDERS' EQUITY

The Company has a common stock repurchase program. Purchases are made on the open market, subject to market conditions, and are funded by available cash or borrowings. All common stock repurchased is retired upon purchase. The Company has a 10b5-1 plan that allows brokers selected by the Company to repurchase shares on behalf of the Company at times when it would ordinarily not be in the market because of the Company's trading policies. The Company repurchased 251 shares of its common stock for $\$ 4,309$ and 563 shares of its common stock for $\$ 7,842$ during the second quarter of fiscal 2007 and 2006 , respectively. Year-to-date, the Company repurchased 961 shares of its common stock for $\$ 15,547$ and 1,169 shares for $\$ 16,401$ in fiscal 2007 and 2006 , respectively. Year-to-date, private party transactions accounted for 18 shares and 111 shares in fiscal 2007 and 2006 , respectively.

$$
-9-
$$

NOTE H - COMPREHENSIVE INCOME

Comprehensive income is comprised of all changes in shareholders' equity during the period other than from transactions with shareholders. Comprehensive income consists of the following:


Other comprehensive income (loss):
Change in fair value of derivative instruments, net of tax

## NOTE I -- COMMITMENTS AND CONTINGENCIES

The Company is not a party to any litigation, other than routine litigation incidental to its business except for the litigation described below. The Company believes that none of the routine litigation, individually or in the aggregate, will be material to the business of the company.

In August 2004, the Company reached a settlement with the United States Federal Trade Commission (FTC) and states' attorneys general offices regarding a now terminated agreement between Alpharma, Inc. and the Company related to a children's ibuprofen suspension product. In connection with the Alpharma, Inc. agreement and the related FTC settlement, the Company has been named as a defendant in three suits, two of which are class actions that have been consolidated with one another (the Direct Purchaser Action), filed on behalf of Company customers (i.e., retailers), and the other consisting of four class action suits (the Indirect Purchaser Action), filed on behalf of indirect Company customers (i.e., consumers), alleging that the plaintiffs overpaid for children's ibuprofen suspension product as a result of the Company's agreement with Alpharma, Inc. On April 24, 2006, the court in the Direct Purchaser Action issued an order and final judgment approving the settlement of this matter with respect to defendants Alpharma, Inc. and the Company. The company agreed to pay $\$ 3,000$ as part of the settlement of the Direct Purchaser Action. Separately, Alpharma, Inc. and the Company entered into a settlement agreement to resolve the Indirect Purchaser Action for a combination of cash and product donations of approximately $\$ 1,000$. On December 11,2006 , the court granted final approval of the settlement for the Indirect Purchaser Action. The Company recorded income of $\$ 500$ in the second quarter of fiscal 2007 for the reduction of the associated accruals and considers all related issues to be closed.

The Company is defending a few remaining individual lawsuits pending in various state and federal courts involving phenylpropanolamine (PPA), an ingredient used in the manufacture of certain OTC cough/cold and diet products. The Company discontinued using PPA in the U.S. in November 2000 at the request of the United States Food and Drug Administration (FDA). These cases allege that the plaintiff suffered injury, generally some type of stroke, from ingesting PPA-containing products. Many of these suits also name other manufacturers or retailers of PPA-containing products. These personal injury suits seek an unspecified amount of compensatory, exemplary and statutory damages. The Company maintains

$$
-10-
$$

product liability insurance coverage for the claims asserted in these lawsuits. The Company believes that it has meritorious defenses to these lawsuits and intends to vigorously defend them. At this time, the Company cannot determine whether it will be named in additional PPA-related suits, the outcome of existing suits or the effect that PPA-related suits may have on its financial condition or operating results.

In addition to the foregoing discussion, the Company has pending certain other legal actions and claims incurred in the normal course of business. The Company believes that it has meritorious defenses to these lawsuits andor is covered by insurance and is actively pursuing the defense thereof. The Company believes the resolution of all of these matters will not have a material adverse effect on

## Edgar Filing: PERRIGO CO - Form 10-Q

its financial condition and results of operations as reported in the accompanying consolidated financial statements. However, depending on the amount and timing of an unfavorable resolution of these lawsuits, the Company's future results of operations or cash flow could be materially impacted in a particular period.

The Company's Israeli subsidiary has provided a guaranty to a bank to secure the debt of a $50 \%$ owned joint venture for approximately $\$ 470$, not to exceed $50 \%$ of the joint venture's debt, that is not recorded on the Company's condensed consolidated balance sheets as of December 30, 2006.

## NOTE J - SEGMENT INFORMATION

The Company has three reportable segments, aligned primarily by product: Consumer Healthcare, Rx Pharmaceuticals and API as well as an Other category. The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses are comprised of certain corporate services that are not allocated to the segments. These corporate services generally relate to executive management, human resources, finance and information technology. Fiscal 2006 unallocated expenses also included one-time acquisition integration costs.

|  | Consumer Healthcare | Rx Pharmaceuticals | API | Other |
| :---: | :---: | :---: | :---: | :---: |
| Second Quarter 2007 |  |  |  |  |
| Net sales | \$275,947 | \$28,260 | \$28,633 | \$37,789 |
| Operating income (loss) | \$17,420 | \$3,686 | \$5,929 | \$2,976 |
| Second Quarter 2006 |  |  |  |  |
| Net sales | \$270,222 | \$28,645 | \$26,863 | \$33,967 |
| Operating income (loss) | \$31,436 | \$5,300 | \$6,545 | \$994 |
| Year-to-Date 2007 |  |  |  |  |
| Net sales | \$517,756 | \$59,685 | \$58, 412 | \$74,991 |
| Operating income (loss) | \$34,520 | \$9,473 | \$10,587 | \$5,640 |
| Year-to-Date 2006 |  |  |  |  |
| Net sales | \$497,322 | \$57,739 | \$53,654 | \$70,716 |
| Operating income (loss) | \$44,762 | \$9,136 | \$13,131 | \$130 |

NOTE K -- RESTRUCTURING

In the fourth quarter of fiscal 2006 , as a result of an ongoing review of its Consumer Healthcare operating strategies, the Company's Board of Directors approved plans to exit two unprofitable product lines, effervescent tablets and psyllium-based laxatives. This action resulted in the sale of one Michigan plant and the closure of an additional Michigan plant, both in the second quarter of fiscal 2007 . The Company recorded a gain of $\$ 1,276$ in the second quarter of fiscal 2007 based on the cash proceeds from the sale of the plant. The gain is included in the restructuring line of the income statement. The Company also recorded a $\$ 1,500$ note receivable from the buyer of the plant. This amount, reflecting further gain on the sale of the plant, has been deferred and will be recognized as the note is repaid over the next five years. In addition, the

## Edgar Filing: PERRIGO CO - Form 10-Q

Company incurred a charge of $\$ 1,918$ in the second quarter of fiscal 2007 for employee-related and plant shutdown costs. The employee-related charge was $\$ 1,151$ for termination benefits for 72 employees. Unpaid termination benefits of $\$ 657$ as of December 30,2006 are expected to be paid over the next six months.

In connection with the Agis acquisition, the Company accrued $\$ 3,933$ of restructuring costs, consisting of employee termination benefits for 60 employees and certain lease termination costs. The Company made payments to employees of $\$ 415$ in the first half of fiscal 2007 . For accounting purposes, these restructuring costs were included in the allocation of the total purchase price. The activity related to these restructuring costs is as follows:

Fiscal 2005 Restructuring


> MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
> SECOND QUARTER FISCAL YEARS 2007 AND 2006
> (in thousands, except per share amounts)

## OVERVIEW

Segments -- The Company has three reportable segments, aligned primarily by product: Consumer Healthcare, Rx Pharmaceuticals and API as well as an Other category. The Consumer Healthcare segment includes the U.S., U.K. and Mexico operations supporting the sale of OTC pharmaceutical and nutritional products worldwide. The Rx Pharmaceuticals segment supports the development and sale of prescription drug products. The API segment supports the development and manufacturing of API products in Israel and Germany, with sales to customers worldwide. The Other category consists of two operating segments, Israel Consumer Products and Israel Pharmaceutical and Diagnostic Products, with sales primarily to the Israeli market, including cosmetics, toiletries, detergents, manufactured and imported pharmaceutical products and medical diagnostic products. Neither of these operating segments meets the quantitative thresholds required to be separately reportable segments.

Seasonality -- The Company's sales of OTC pharmaceutical and nutritional products are subject to the seasonal demands for cough/cold/flu and allergy products. Accordingly, operating results for the first half of fiscal 2007 are not necessarily indicative of the results that may be expected for a full year.

Current Year Results -- Net sales for the second quarter of fiscal 2007 were $\$ 370,629$, an increase of $3 \%$ over fiscal 2006 . The increase was driven primarily by the Consumer Healthcare segment and Other category. New product sales for the second quarter of fiscal 2007 were approximately $\$ 23,000$. Gross profit was $\$ 98,325$, a decrease of $7 \%$ over fiscal 2006 . The gross profit percentage in the

## Edgar Filing: PERRIGO CO - Form 10-Q

second quarter of fiscal 2007 was 26.5\%, down from 29.3\% last year. Operating expenses in the second quarter of fiscal 2007 were $\$ 71,938$, an increase of $9 \%$ over fiscal 2006, and included a net restructuring charge of $\$ 642$. Operating expenses as a percent of net sales were 19.4\%, up from 18.4\% in the second quarter of fiscal 2006. Net income was $\$ 21,088$, a decrease of $17 \%$ from fiscal 2006. The second quarter of fiscal 2007 was negatively impacted by the acetaminophen product recall, the effect of which was partially offset by the favorable effective tax. Fiscal 2006 included a gain from the sale of the Company's non-controlling interest in Shandex Sales Group Ltd. (Canada).

Net sales for the first half of fiscal 2007 were $\$ 710,844$, an increase of $5 \%$ over fiscal 2006. The increase spanned all of the Company's segments and included new product sales of approximately $\$ 33,000$. Gross profit was essentially unchanged from fiscal 2006 . The gross profit percentage in the first half of fiscal 2007 was $27.1 \%$, down from $28.3 \%$ last year. Operating expenses were $\$ 140,843$, an increase of $6 \%$ over fiscal 2006 and up slightly as a percent of net sales over fiscal 2006. Net income was $\$ 37,970$, a decrease of $1 \%$ from fiscal 2006. The first half of fiscal 2007 was negatively impacted by the acetaminophen product recall, the effect of which was partially offset by the favorable effective tax rate.

Further details related to current year results are included in the following Results of Operations.

$$
-13-
$$

Product Recall -- On November 9, 2006, the Company initiated a voluntary retail-level recall of certain lots of its acetaminophen 500 mg caplets containing raw material purchased from a third party supplier. The Company's quality control systems noted trace amounts of metal particulate in a very small number of these caplet products. The probability of health risk is extremely remote. Following the announcement of the recall, the Company received numerous consumer inquiries, and in order to properly address these inquiries, voluntarily initiated a consumer level return program in addition to the retail returns process. The total cost of the recall is estimated to be approximately $\$ 6,000$ and has been recorded in the first half of fiscal 2007. The charge included sales returns and refunds, handling of on-hand inventories, disposal of inventory and management of consumer inquiries. The total charge recorded in the second quarter of fiscal 2007 was approximately $\$ 5,000$. This product recall related to the Consumer Healthcare segment. While the Company believes its estimate of the total cost of the recall is reasonable, the Company cannot predict whether this recall will have any further impact on its results of operations.

Pseudoephedrine -- The Company continued to be impacted by the legislative and market concerns related to products containing pseudoephedrine, which have resulted from concerns over the use of pseudoephedrine in the production of methamphetamine, an illegal drug. Sales of these products for the first half of fiscal 2007 were approximately $\$ 51,000$ lower than the first half of fiscal 2006. Sales of pseudoephedrine products are expected to be $\$ 30,000$ to $\$ 35,000$ for fiscal 2007, excluding expected sales of pseudoephedrine replacement products.

|  | Second Quarter |  |
| :--- | :---: | :---: |
|  | -2007 | 2006 |
| Net sales | $\$ 275,947$ | $\$ 270,222$ |
| Gross profit |  |  |
| Gross profit \% | $\$ 59,346$ | $\$ 69,729$ |
| Operating expenses | $21.5 \%$ | $25.8 \%$ |
| Operating expenses \% | $\$ 41,926$ | $\$ 38,293$ |
| Operating income | $15.2 \%$ | $14.2 \%$ |
| Operating income $\%$ | $\$ 17,420$ | $\$ 31,436$ |
|  | $6.3 \%$ | $11.6 \%$ |

Net Sales

Second quarter net sales for fiscal 2007 increased $2 \%$ or $\$ 5,725$ compared to fiscal 2006. The increase was comprised of $\$ 7,000$ of international sales, offset by an approximate $\$ 1,300$ decrease in domestic sales. The increase in
international sales resulted from higher unit sales of existing products as well as $\$ 1,600$ from favorable foreign currency exchange. The slight decrease in domestic sales was driven by a $\$ 12,400$ decrease in the combination of pseudoephedrine and phenylephrine-containing products along with lower unit sales of existing products in the analgesics, gastrointestinal, and nutrition product categories of $\$ 10,600$. These domestic decreases were mostly offset by $\$ 19,500$ of new product sales in the smoking cessation, gastrointestinal and nutrition categories along with a $\$ 2,200$ increase in higher unit sales of existing products in the cough/cold category compared to the second quarter of fiscal 2006.

Year-to-date net sales for fiscal 2007 increased $4 \%$ or $\$ 20,434$ compared to fiscal 2006. The increase was comprised of $\$ 12,700$ of international sales and $\$ 7,700$ of domestic sales. The increase in international sales resulted from higher unit sales of existing products as well as $\$ 2,300$ from favorable foreign currency exchange. The domestic increase resulted from $\$ 26,800$ of new product sales in the smoking cessation, gastrointestinal and nutrition categories along with an $\$ 8,600$ increase from higher unit sales of existing products in the smoking cessation and cough/cold categories. These combined domestic increases were partially offset by an $\$ 8,800$ decrease in lower unit sales of existing products in the gastrointestinal and nutrition product categories along with sales declines from the combination of pseudoephedrine and phenylephrine-containing products of $\$ 18,600$ in fiscal 2007 compared to fiscal 2006.

The Company continued to be impacted by the legislative and market changes related to products containing pseudoephedrine, which have resulted from concerns over the use of pseudoephedrine in the production of methamphetamine, an illegal drug. Net sales of these products in the first half of fiscal 2007 were approximately $\$ 51,000$ lower than the first half of fiscal 2006 . Net sales of pseudoephedrine products are expected to be $\$ 30,000$ to $\$ 35,000$ for fiscal 2007, excluding expected sales of pseudoephedrine replacement products.

## Edgar Filing: PERRIGO CO - Form 10-Q

## Gross Profit

Second quarter gross profit for fiscal 2007 decreased 15\% or $\$ 10,383$ compared to fiscal 2006. Year-to-date gross profit for fiscal 2007 decreased $6 \%$ or $\$ 6,826$ compared to fiscal 2006. The decrease was primarily due to higher than expected costs for production and quality, the unfavorable margin impact from lower unit sales of pseudoephedrine-containing products and the acetaminophen product recall (described below). These decreases were partially offset by the gross profit on increased sales volume attributed to new products and international sales.

On November 9, 2006, the Company initiated a voluntary retail-level recall of certain lots of its acetaminophen 500 mg caplets containing raw material purchased from a third party supplier. The Company's quality control systems noted trace amounts of metal particulate in a very small number of these caplet products. The probability of health risk is extremely remote. Following the announcement of the recall, the company received numerous consumer inquiries, and in order to properly address these inquiries, voluntarily initiated a consumer level return program in addition to the retail returns process. The total cost of the recall is estimated to be approximately $\$ 6,000$ and has been recorded in the first half of fiscal 2007 . The charge included sales returns and refunds, handling of on-hand inventories, disposal of inventory and management of consumer inquiries. The total charge recorded in the second quarter of fiscal 2007 was approximately $\$ 5,000$. While the Company believes its estimate of the total cost of the recall is reasonable, the Company cannot predict whether this recall will have any further impact on its results of operations.

## Operating Expenses

Second quarter operating expenses for fiscal 2007 increased 9\% or $\$ 3,633$ compared to fiscal 2006. Year-to-date operating expenses for fiscal 2007 increased $4 \%$ or $\$ 3,416$ compared to fiscal 2006 . The increases were primarily due to higher employee wages, recruiting and relocation costs. Year-to-date operating expenses as a percent of net sales remained flat compared to fiscal 2006.

## RX PHARMACEUTICALS

|  | Second Quarter |  |
| :---: | :---: | :---: |
|  | 2007 | 2006 |
| Net sales | \$28, 260 | \$28, 645 |
| Gross profit | \$11,387 | \$11,592 |
| Gross profit \% | $40.3 \%$ | $40.5 \%$ |
| Operating expenses | \$7,701 | \$6,292 |
| Operating expenses \% | 27.3\% | 22.0\% |
| Operating income | \$3,686 | \$5,300 |
| Operating income \% | 13.0\% | 18.5\% |

Net Sales
Second quarter net sales for fiscal 2007 decreased $1 \%$ or $\$ 385$ compared to fiscal 2006. Service and royalty revenues were $\$ 6,000$ more than fiscal 2006 and were

# Edgar Filing: PERRIGO CO - Form 10-Q 

offset by an increase in expense for customer-related programs.

Year-to-date net sales for fiscal 2007 increased $3 \%$ or $\$ 1,946$ compared to fiscal 2006. This increase was primarily due to an increase in service and royalty revenues of approximately $\$ 11,000$, partially offset by pricing pressure on current products sold under Abbreviated New Drug Applications (ANDA) and an increase in expense for customer-related programs of $\$ 5,000$. Fiscal 2006 was unfavorably impacted by a mesalamine product recall (described below) that decreased sales $\$ 1,350$.

Fiscal 2007 results include an increase in expense related to the Company's customer programs in the Rx Pharmaceuticals segment as noted above. Customer programs are common in the industry and include such items as rebates and chargebacks. The determination of the liability for these programs involves a significant amount of estimation. The Company has a methodology by which it accrues and validates its accrual of these expenses. This methodology includes several variables: inventory reports supplied by wholesalers that indicate inventory levels, detailed computations using historical payments and estimated sell-through to retailers with varying contract prices. The Company has been monitoring its methodology and made material changes to certain of these estimates in the second quarter of fiscal 2007 that led to the current quarter charges. The changes to the estimates are intended to further enhance the accuracy and reliability of the calculation of the liability and to reduce the risk of incremental charges for customer programs beyond the current quarter charge.

Gross Profit

Second quarter gross profit for fiscal 2007 was virtually unchanged when compared to fiscal 2006. The impact on gross profit of the increase in expense for customer programs was offset by the increase in service and royalty revenues.

Year-to-date gross profit for fiscal 2007 increased $8 \%$ or $\$ 1,957$ compared to fiscal 2006 . The increase was due primarily to the increase in service and royalty revenues and the absence of the mesalamine product recall, partially offset by pricing pressure on current ANDA products and the increase in expense for customer programs.

In the first quarter of fiscal 2006, the Company initiated a voluntary retail-level recall of all affected lots of mesalamine rectal suspension, an anti-inflammatory agent used to treat mild to moderate ulcerative colitis, following reports of leakage related to the bottle closure cap. The recall was not safety related and there have been no reports of injury or illness related to the leakage of this product. The costs to write off the value of the Company's on-hand inventories and the costs of return and disposal, estimated to be $\$ 2,750$, were recorded in the first quarter of fiscal 2006 . No further expense is expected to be incurred related to this recall.

## Operating Expenses

Second quarter operating expenses for fiscal 2007 increased $22 \%$ or $\$ 1,409$ compared to fiscal 2006. Year-to-date operating expenses for fiscal 2007 increased $12 \%$ or $\$ 1,620$ compared to fiscal 2006 . The increase in both periods was primarily due to higher spending for research and development.

# Edgar Filing: PERRIGO CO - Form 10-Q 

## -17-

AP I

|  | Second Quarter |  | Year-to-Date |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2007 | 2006 | 2007 | 2006 |
| Net sales | \$28,633 | \$26,863 | \$58,412 | \$53,654 |
| Gross profit | \$14,085 | \$12,797 | \$25,964 | \$24,801 |
| Gross profit \% | 49.2\% | 47.6\% | 44.4\% | 46.2\% |
| Operating expenses | \$8,156 | \$6,252 | \$15,377 | \$11,670 |
| Operating expenses \% | 28.5\% | 23.3\% | 26.3\% | 21.8\% |
| Operating income | \$5,929 | \$6,545 | \$10,587 | \$13,131 |
| Operating income \% | 20.7\% | 24.4\% | 18.1\% | 24.5\% |

Net Sales
Second quarter net sales for fiscal 2007 increased $7 \%$ or $\$ 1,770$ compared to fiscal 2006. This increase was primarily due to sales of new products and increased sales of existing products in the European and Japanese markets. These increases were partially offset by a decline in pentoxifylline sales.

Year-to-date net sales for fiscal 2007 increased 9\% or $\$ 4,758$ compared to fiscal 2006. This increase was due to sales of new products of approximately $\$ 2,000$. The remaining increase was due to customer and product mix changes, including strong sales in the European market and the introduction of existing products into new geographic markets, partially offset by a decline in pentoxifylline sales. The net sales of API are highly dependent on the level of competition in the marketplace for a specific material. The current trend of increased sales may not continue due to this dependency.

## Gross Profit

Second quarter gross profit for fiscal 2007 increased $10 \%$ or $\$ 1,288$ compared to fiscal 2006. This increase was primarily due to the gross profit on increased volume attributable to new products combined with changes in customer and product mix.

Year-to-date gross profit for fiscal 2007 increased $5 \%$ or $\$ 1,163$ compared to fiscal 2006. This increase was primarily due to the fiscal 2006 charge of $\$ 1,747$ for the write-off of the step-up in the value of inventory resulting from the Agis acquisition along with the gross profit on increased volume attributable to new products. These increases were partially offset by changes in customer and product sales mix.

## Operating Expenses

Second quarter operating expenses for fiscal 2007 increased $30 \%$ or $\$ 1,904$ compared to fiscal 2006. Year-to-date operating expenses for fiscal 2007 increased $32 \%$ or $\$ 3,707$ compared to fiscal 2006 . The increase was primarily due to spending for increased research and development and higher sales commissions.

## Edgar Filing: PERRIGO CO - Form 10-Q

## OTHER

The Other category includes two operating segments: Israel Consumer Products and Israel Pharmaceutical and Diagnostic Products. Neither of these operating segments individually meets the quantitative thresholds required to be a reportable segment.

|  | Second Quarter |  | Year-to-Date |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2007 | 2006 | 2007 | 2006 |
| Net sales | \$37,789 | \$33,967 | \$74,991 | \$70,716 |
| Gross profit | \$13,507 | \$11,452 | \$26,257 | \$22,095 |
| Gross profit \% | 35.7\% | 33.7\% | 35.0\% | 31.2\% |
| Operating expenses | \$10,531 | \$10,458 | \$20,617 | \$21,965 |
| Operating expenses \% | 27.8\% | 30.8\% | 27.5\% | 31.1\% |
| Operating income | \$2,976 | \$994 | \$5,640 | \$130 |
| Operating income \% | 7.9\% | 2.9\% | 7.5\% | $0.2 \%$ |

Second quarter net sales for fiscal 2007 increased $11 \%$ or $\$ 3,822$ compared to fiscal 2006 primarily due to changes in the foreign exchange rate and higher volume in the Consumer Products business. Second quarter gross profit for fiscal 2007 increased $18 \%$ or $\$ 2,055$ compared to fiscal 2006 , half of which was due to changes in the foreign exchange rate and the other to a more favorable mix of products sold in the Consumer Products business.

Year-to-date net sales for fiscal 2007 increased $6 \%$ or $\$ 4,275$ compared to fiscal 2006 due to changes in the foreign exchange rate and higher volume in the Consumer Products business. Year-to-date gross profit for fiscal 2007 increased $19 \%$ or $\$ 4,162$ compared to fiscal 2006.

The year-to-date gross profit for fiscal 2006 included a charge of $\$ 2,697$ for the write-off of the step-up in the value of inventory resulting from the Agis acquisition. The remainder of the gross profit increase was due to changes in the foreign exchange rate. Year-to-date operating expenses for fiscal 2007 decreased $6 \%$ or $\$ 1,348$ compared to fiscal 2006 primarily due to lower sales commissions and administration expenses.

## UNALLOCATED EXPENSES

Unallocated expenses were comprised of certain corporate services that were not allocated to the segments. These corporate services generally related to executive management, human resources, finance and information technology. Unallocated expenses for the second quarter decreased $27 \%$ or $\$ 1,342$ compared to fiscal 2006. The second quarter of fiscal 2006 included acquisition integration costs of $\$ 1,400$. Year-to-date unallocated expenses increased $14 \%$ or $\$ 1,000$ compared to fiscal 2006 primarily due to higher wages and benefits. Year-to-date fiscal 2006 included acquisition integration costs of $\$ 2,000$.

## Edgar Filing: PERRIGO CO - Form 10-Q

## INTEREST AND OTHER (CONSOLIDATED)

Interest expense for the second quarter was $\$ 8,431$ for fiscal 2007 and $\$ 10,089$ for fiscal 2006. Interest income for the second quarter was $\$ 5,131$ for fiscal 2007 and $\$ 4,973$ for fiscal 2006. Other income was $\$ 2,258$ for the second quarter of fiscal 2007 compared to $\$ 5,791$ for the second quarter of fiscal 2006 .

$$
-19-
$$

Other income for the second quarter of fiscal 2006 included a gain of $\$ 4,666$ from the sale of an equity investment.

Year-to-date interest expense was $\$ 17,771$ for fiscal 2007 and $\$ 19,593$ for fiscal 2006. Year-to-date interest income was $\$ 9,885$ for fiscal 2007 and $\$ 10,451$ for fiscal 2006. Year-to-date other income was $\$ 2,319$ and $\$ 7,037$ for fiscal 2007 and 2006, respectively. Other income for fiscal 2006 included a gain of $\$ 4,666$ from the sale of an equity investment.

## INCOME TAXES (CONSOLIDATED)

The second quarter effective tax rate was $16.8 \%$ for fiscal 2007 and $36.6 \%$ for fiscal 2006. Year-to-date the effective tax rate was $18.4 \%$ for fiscal 2007 and $33.9 \%$ for fiscal 2006. The Company's international expansion has changed the relative composition of U.S. and Foreign income resulting in a lower effective tax rate than the Company had historically experienced. This tax rate will fluctuate from quarter to quarter depending on the composition of income before tax. Eighty percent of income before tax in the first half of fiscal 2007 was contributed by foreign entities with a tax rate lower than the U.S. statutory rate. The effective tax rate for succeeding quarters is expected to be higher as the Company's U.S. income is likely to constitute a higher percentage of the total income than in the first half of fiscal 2007 . The Company estimates the annualized effective tax rate for fiscal 2007 is between $20 \%$ and $23 \%$.

Additionally, the effective tax rate for the second quarter of fiscal 2007 included the impact of the newly enacted Tax Relief and Healthcare Act of 2006 (the Act). Among other provisions, the Act provides for the restoration of the research and development tax credit, applied retroactively to January 1, 2006. Accordingly, tax expense in the second quarter of fiscal 2007 was reduced approximately $\$ 1,300$ to reflect the one-time impact of the retroactive application of the Act.

## FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash, cash equivalents and investment securities increased $\$ 47,108$ to $\$ 73,665$ at December 30,2006 from $\$ 26,557$ at December 24,2005 . Working capital, including cash, increased $\$ 111,518$ to $\$ 366,107$ at December 30, 2006 from $\$ 254,589$ at December 24, 2005. The increase in working capital was due primarily to the build-up of new product and reformulation inventory.

Year-to-date net cash provided from operating activities decreased by $\$ 37,603$ to $\$ 17,635$ for fiscal 2007 compared to $\$ 55,238$ for fiscal 2006 . The decreased cash from operations was primarily related to the strategic build-up of inventories and an increase in employee bonuses paid as a result of fiscal 2006 operating results. Inventory levels tend to be higher in the first half of the fiscal year as the Company's operations focus on meeting customer requirements during peak demand of the cough/cold/flu season. In addition, the Company was building inventory in Israel to support demand through the implementation of its enterprise resource planning system.

Year-to-date net cash used for investing activities increased \$17,839 to \$23,252 for fiscal 2007 compared to $\$ 5,413$ for fiscal 2006 primarily due to higher capital expenditures and a net increase in the purchase of investment securities.

Year-to-date capital expenditures for facilities and equipment were for normal replacement and productivity enhancements. Capital expenditures are anticipated to be $\$ 40,000$ to $\$ 50,000$ for fiscal 2007 . The annual capital expenditures for fiscal 2006 were $\$ 36,000$.

$$
-20-
$$

Year-to-date net cash provided from financing activities increased \$69,482 to $\$ 23,279$ for fiscal 2007 compared to cash used for financing activities of $\$ 46,203$ for fiscal 2006. The increased cash from financing activities was primarily due to increased net borrowings of long-term debt to fund the Company's working capital requirements.

The Company repurchased 251 shares of its common stock for $\$ 4,309$ and 563 shares for $\$ 7,842$ during the second quarter of fiscal 2007 and 2006 , respectively. Year-to-date, the Company repurchased 961 shares of its common stock for $\$ 15,547$ and 1,169 shares for $\$ 16,401$ in fiscal 2007 and 2006, respectively. Private party transactions accounted for 5 shares and 1 share in the second quarter of fiscal 2007 and 2006, respectively. Year-to-date, private party transactions accounted for 18 shares and 111 shares in fiscal 2007 and 2006 , respectively.

The Company paid quarterly dividends totaling $\$ 8,116$ and $\$ 7,702$, or $\$ 0.0875$ and $\$ 0.0825$ per share, for the first half of fiscal 2007 and 2006 , respectively. The declaration and payment of dividends, if any, is subject to the discretion of the Board of Directors and will depend on the earnings, financial condition and capital and surplus requirements of the Company and other factors the Board of Directors may consider relevant.

## GUARANTIES AND CONTRACTUAL OBLIGATIONS

The Company's Israeli subsidiary has provided a guaranty to a bank to secure the debt of a $50 \%$ owned joint venture for approximately $\$ 470$, not to exceed $50 \%$ of the joint venture's debt, that is not recorded on the Company's condensed consolidated balance sheets as of December 30, 2006.

During the second quarter of fiscal 2007, no material change in contractual obligations occurred.

## CRITICAL ACCOUNTING POLICIES

Determination of certain amounts in the Company's financial statements requires the use of estimates. These estimates are based upon the Company's historical experiences combined with management's understanding of current facts and circumstances. Although the estimates are considered reasonable, actual results could differ from the estimates. The accounting policies, discussed below, are considered by management to require the most judgment and are critical in the preparation of the financial statements. Other significant accounting policies are included in Note $A$ of the notes to the consolidated financial statements in the Company's annual report on Form 10-K for the fiscal year ended July 1, 2006.

Revenue Recognition and Customer Programs -- The Company records revenues from product sales when the goods are shipped to the customer. For customers with Free on Board destination terms, a provision is recorded to exclude shipments estimated to be in-transit to these customers at the end of the reporting

## Edgar Filing: PERRIGO CO - Form 10-Q

period. A provision is recorded and accounts receivable are reduced as revenues are recognized for estimated losses on credit sales due to customer claims for discounts, price discrepancies, returned goods and other items. A liability is recorded as revenues are recognized for estimated customer program liabilities, as discussed below.

A chargeback relates to an agreement the Company has with a wholesaler, a retail customer that will ultimately purchase product from a wholesaler or a pharmaceutical buying group for a contracted price that is different than the Company's price to the wholesaler. The wholesaler will issue an invoice to the Company for the difference in the contract prices. The calculation of the accrual for chargebacks includes several variables: inventory reports supplied by wholesalers that indicate inventory levels, detailed
-21-
computations using historical payments and estimated sell-through to retailers with varying contract prices.

Rebates are payments issued to the customer when certain criteria are met which may include specific levels of product purchases, introduction of new products or other objectives. The accrual for rebates is based on contractual agreements and estimated purchasing levels by customers with such programs. Medicaid rebates are payments made to states for pharmaceutical products covered by the program. The accrual for Medicaid rebates is based on historical trends of rebates paid and current period sales activity.

Shelf stock adjustments are credits issued to reflect decreases in the selling price of a product and are based upon estimates of the amount of product remaining in a customer's inventory at the time of the anticipated price reduction. In many cases, the customer is contractually entitled to such a credit. The accrual for shelf stock adjustments is based on specified terms with certain customers, estimated launch dates of competing products and estimated declines in market price.

The Company has a methodology by which it accrues and validates its accrual of these liabilities. The Company has been monitoring its methodology and made material changes to certain of the estimates in the second quarter of fiscal 2007 that resulted in additional accruals. The changes to the estimates are intended to further enhance the accuracy and reliability of the calculation of the liability and to reduce the risk of incremental charges for customer programs. However, future changes in the estimates and assumptions related to these programs may result in additional accruals.

The following table summarizes the activity included in the balance sheet for accounts receivable allowances and customer program accruals:

|  | $\begin{aligned} & \text { Year-to-Date } \\ & 2007 \end{aligned}$ | $\begin{gathered} \text { Year-to-Date } \\ 2006 \end{gathered}$ |
| :---: | :---: | :---: |
| Balance, beginning of period | \$54,456 | \$48,378 |
| Provision recorded | 97,125 | 75,957 |
| Credits processed | $(103,676)$ | $(67,310)$ |
| Balance, end of the period | \$47,905 | \$57,025 |

## Edgar Filing: PERRIGO CO - Form 10-Q

Allowance for Doubtful Accounts -- The Company maintains an allowance for customer accounts that reduces receivables to amounts that are expected to be collected. In estimating the allowance, management considers factors such as current overall economic conditions, industry-specific economic conditions, historical and anticipated customer performance, historical experience with write-offs and the level of past-due amounts. Changes in these conditions may result in additional allowances. The allowance for doubtful accounts was \$12,198 at December 30, 2006, \$11,178 at July 1, 2006, and \$11,088 at December 24, 2005.

Inventory -- The Company maintains an allowance for estimated obsolete or unmarketable inventory based on the difference between the cost of the inventory and its estimated market value. In estimating the allowance, management considers factors such as excess or slow moving inventories, product expiration dating, products on quality hold, current and future customer demand and market conditions. Changes in these conditions may result in additional allowances. The allowance for inventory was $\$ 39,098$ at December 30, 2006, \$42,509 at July 1, 2006 and $\$ 44,201$ at December 24, 2005.

$$
-22-
$$

Goodwill -- Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. The test for impairment requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The estimates associated with the goodwill impairment tests are considered critical due to the judgments required in determining fair value amounts, including projected future cash flows. Changes in these estimates may result in the recognition of an impairment loss. Goodwill allocated to the Consumer Healthcare segment is tested annually for impairment in the second quarter of the fiscal year. The current year testing resulted in no impairment charge related to the Consumer Healthcare segment. The goodwill allocated to the API and Rx Pharmaceuticals segments is tested for impairment annually in the third quarter of the fiscal year. Goodwill was $\$ 188,272$ at December 30, 2006, \$152,183 at July 1,2006 and $\$ 150,067$ at December 24, 2005.

Other Intangible Assets -- Other intangible assets subject to amortization consist of developed product technology, distribution and license agreements, customer relationships and trademarks. Most of these assets are related to the Agis acquisition and are amortized over their estimated useful economic lives using the straight-line method. An accelerated method of amortization is used for customer relationships. For intangible assets subject to amortization, an impairment analysis is performed whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset is not recoverable and its carrying amount exceeds its fair value. Other intangible assets were $\$ 134,187$ at December 30, 2006, \$132,426 at July 1, 2006 and $\$ 141,079$ at December 24, 2005.

Product Liability and Workers' Compensation -- The Company maintains accruals to provide for claims incurred that are related to product liability and workers' compensation. In estimating these accruals, management considers actuarial valuations of exposure based on loss experience. These actuarial valuations include significant estimates and assumptions, which include, but are not limited to, loss development, interest rates, product sales, litigation costs, accident severity and payroll expenses. Changes in these estimates and assumptions may result in additional accruals. The accrual for product liability claims was $\$ 2,926$ at December 30, 2006, \$1,937 at July 1, 2006 and $\$ 2,420$ at December 24, 2005. The accrual for workers' compensation claims was $\$ 1,662$ at

December 30, 2006, \$1,919 at July 1, 2006 and $\$ 2,987$ at December 24, 2005 .

$$
-23-
$$

Item 3. Quantitative and Qualitative Disclosures About Market Risks
The Company is exposed to market risks due to changes in currency exchange rates and interest rates.

The Company is exposed to interest rate changes primarily as a result of interest expense on borrowings used to finance the Agis acquisition and working capital requirements and interest income earned on its investment of cash on hand. As of December 30, 2006, the Company had invested cash, cash equivalents and investment securities of $\$ 73,665$ and short and long-term debt, net of restricted cash, of $\$ 287,117$.

The Company enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure, particularly related to the management of interest rate risk. Because of the use of certain derivative financial instruments, the Company believes that a significant fluctuation in interest rates in the near future will not have a material impact on the Company's consolidated financial statements. These instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Derivative financial instruments are not used for speculative purposes. Gains and losses on hedging transactions are offset by gains and losses on the underlying exposures being hedged.

The Company has operations in the U.K., Israel, Germany and Mexico. These operations transact business in their local currency and foreign currencies, thereby creating exposures to changes in exchange rates. From time to time, the Company enters into currency derivative instruments to hedge its underlying exposure to currency fluctuations. Significant currency fluctuations could adversely impact foreign revenues; however, the company cannot predict future changes in foreign currency exposure.

$$
-24-
$$

Item 4. Controls and Procedures

As of December 30, 2006, the Company's management, including its Chief Executive Officer and its Chief Financial Officer, has performed an interim review on the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that review, as well as an evaluation and consideration of the update described below, the Chief Executive Officer and Chief Financial Officer have concluded the Company's disclosure controls and procedures are effective in ensuring that all material information relating to the Company and its consolidated subsidiaries required to be included in the Company's periodic SEC filings would be made known to them by others within those entities in a timely manner and that no changes are required at this time.

Following is an update of the remediation plan related to the Company's fiscal 2005 Agis acquisition which should be read in conjunction with Item 9A. Controls and Procedures included in the Company's Form $10-\mathrm{K}$ for the fiscal year ended July 1, 2006.

- The Company's implementation of an enterprise resource planning (ERP) system at its Israeli location which is intended to remediate the majority of the previously disclosed weaknesses was completed in the second quarter of fiscal 2007.
- The Company continues to make minor changes in its control processes to reduce reliance on spreadsheets for financial reporting, improve segregation of duties issues and alleviate other less critical control deficiencies.

In connection with the interim evaluation by the Company's management, including its Chief Executive Officer and Chief Financial Officer, of the Company's internal control over financial reporting (ICFR) pursuant to Rule $13 a-15(d)$ of the Securities Exchange Act of 1934, no changes during the quarter ended December 30 , 2006 were identified that have materially affected, or are reasonably likely to materially affect, the Company's ICFR, other than the implementation of an ERP system at its Israeli location noted above.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

In August 2004, the Company reached a settlement with the FTC and states' attorneys general offices regarding a now terminated agreement between Alpharma, Inc. and the Company related to a children's ibuprofen suspension product. In connection with the Alpharma, Inc. agreement and the related FTC settlement, the Company has been named as a defendant in three suits, two of which are class actions that have been consolidated with one another (the Direct Purchaser Action), filed on behalf of Company customers (i.e., retailers), and the other consisting of four class action suits (the Indirect Purchaser Action), filed on behalf of indirect Company customers (i.e., consumers), alleging that the plaintiffs overpaid for children's ibuprofen suspension product as a result of the Company's agreement with Alpharma, Inc. On April 24, 2006, the court in the Direct Purchaser Action issued an order and final judgment approving the settlement of this matter with respect to defendants Alpharma, Inc. and the Company. The Company agreed to pay $\$ 3,000$ as part of the settlement of the Direct Purchaser Action. Separately, Alpharma, Inc. and the Company entered into a settlement agreement to resolve the Indirect Purchaser Action for a combination of cash and product donations of approximately $\$ 1,000$. On December 11, 2006, the court granted final approval of the settlement for the Indirect Purchaser Action. The Company recorded income of $\$ 500$ in the second quarter of fiscal 2007 for the reduction of the associated accruals and considers all related issues to be closed.

Item 1A. Risk Factors
The Company's Annual Report on Form $10-\mathrm{K}$ filed for the fiscal year ended July 1 , 2006 includes a detailed discussion of the Company's risk factors. Other than the risk factor noted below, there have been no material changes to the risk factors that were included in the Form $10-K$ during the first half of fiscal 2007.

## MDS Pharma Services

MDS Pharma Services (MDS) is a contract research organization that performs studies related to the bioequivalency of drugs. The Company has engaged MDS in

## Edgar Filing: PERRIGO CO - Form 10-Q

the past to perform these types of studies as part of the approval process for certain drugs. Recently, the FDA notified the Company and many other pharmaceutical companies about some concerns over the reliability of studies conducted between 2000 and 2004. The FDA has requested that the affected companies validate, confirm or repeat certain bioequivalence studies. The Company expects that the costs associated with confirming or repeating these studies will be reimbursed by MDS. The FDA has given no indication that it considers the affected products to be other than safe and effective. Because the outcome of the issue is uncertain, the Company cannot predict whether this issue will have a material impact on its results of operations.

$$
-26-
$$

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On February 15, 2006, the Board of Directors approved an additional plan to repurchase shares of common stock with a value of up to $\$ 60,000$. This plan will expire on February 17, 2007. The Company has a 10b5-1 plan that allows brokers selected by the Company to repurchase shares on behalf of the company at times when it would ordinarily not be in the market because of the Company's trading policies. The amount of common stock repurchased in accordance with the $10 b 5-1$ plan on any given day is determined by the plan's formula which is generally based on the market price of the Company's stock. All common stock repurchased is retired upon purchase.

The table below lists the Company's repurchases of shares of common stock during its most recently completed quarter:

Fiscal 2007

| October 1 to November 4 |  |  |  |
| :--- | ---: | ---: | ---: |
| November 5 to December 2 | 81 | $\$ 17.41$ | 77 |
| December 3 to December 30 | 94 | $\$ 17.12$ | 93 |
|  | 76 | $\$ 16.88$ | 76 |
| Total |  | --- |  |

Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans

246

Value of Shares Available
for Purchase
\$43, 087
$\$ 41,674$
\$40,060
\$38,778
(1) Private party transactions accounted for the purchase of 4 shares in the period from October 1 to November 4 and 1 share in the period from November 5 to December 2 .

Item 4. Submission of Matters to a Vote of Security Holders

At the Company's Annual Shareholders' Meeting held on November 10, 2006, the Company's shareholders voted on the following matter:

1. Election of three directors of the Company:

The tabulation of votes provided by the Inspector of Election was as follows:

# Edgar Filing: PERRIGO CO - Form 10-Q 



## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PERRIGO COMPANY
(Registrant)

Date: February 1, 2007
By: /s/ Joseph C. Papa
------------------------------------------
Joseph C. Papa
President and Chief Executive Officer

## Edgar Filing: PERRIGO CO - Form 10-Q

Date: February 1, 2007

By: /s/ Judy L. Brown

Judy L. Brown
Executive Vice President and Chief
Financial Officer
(Principal Accounting and Financial Officer)

